190 related articles for article (PubMed ID: 27399926)
41. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
42. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
Liu C; Tyrrell JB
Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
[TBL] [Abstract][Full Text] [Related]
43. Practical management of peripartum cardiomyopathy.
Kim MJ; Shin MS
Korean J Intern Med; 2017 May; 32(3):393-403. PubMed ID: 28407464
[TBL] [Abstract][Full Text] [Related]
44. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
45. Peripartum cardiomyopathy.
Honigberg MC; Givertz MM
BMJ; 2019 Jan; 364():k5287. PubMed ID: 30700415
[TBL] [Abstract][Full Text] [Related]
46. Cabergoline therapy for Cushing disease throughout pregnancy.
Woo I; Ehsanipoor RM
Obstet Gynecol; 2013 Aug; 122(2 Pt 2):485-487. PubMed ID: 23884269
[TBL] [Abstract][Full Text] [Related]
47. Recovery from peripartum cardiomyopathy after treatment with bromocriptine.
Habedank D; Kühnle Y; Elgeti T; Dudenhausen JW; Haverkamp W; Dietz R
Eur J Heart Fail; 2008 Nov; 10(11):1149-51. PubMed ID: 18926768
[TBL] [Abstract][Full Text] [Related]
48. Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion.
Jahns BG; Stein W; Hilfiker-Kleiner D; Pieske B; Emons G
Am J Obstet Gynecol; 2008 Oct; 199(4):e5-6. PubMed ID: 18928969
[TBL] [Abstract][Full Text] [Related]
49. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.
Bauersachs J; König T; van der Meer P; Petrie MC; Hilfiker-Kleiner D; Mbakwem A; Hamdan R; Jackson AM; Forsyth P; de Boer RA; Mueller C; Lyon AR; Lund LH; Piepoli MF; Heymans S; Chioncel O; Anker SD; Ponikowski P; Seferovic PM; Johnson MR; Mebazaa A; Sliwa K
Eur J Heart Fail; 2019 Jul; 21(7):827-843. PubMed ID: 31243866
[TBL] [Abstract][Full Text] [Related]
50. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities.
Moulig V; Pfeffer TJ; Ricke-Hoch M; Schlothauer S; Koenig T; Schwab J; Berliner D; Pfister R; Michels G; Haghikia A; Falk CS; Duncker D; Veltmann C; Hilfiker-Kleiner D; Bauersachs J
Eur J Heart Fail; 2019 Dec; 21(12):1534-1542. PubMed ID: 31724271
[TBL] [Abstract][Full Text] [Related]
51. Peripartum cardiomyopathy.
Bews H; Saeed M; Liu S
CMAJ; 2021 Nov; 193(45):E1733. PubMed ID: 34782377
[No Abstract] [Full Text] [Related]
52. Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction.
Haghikia A; Schwab J; Vogel-Claussen J; Berliner D; Pfeffer T; König T; Zwadlo C; Moulig VA; Franke A; Schwarzkopf M; Ehlermann P; Pfister R; Michels G; Westenfeld R; Stangl V; Kühl U; Podewski E; Kindermann I; Böhm M; Sliwa K; Hilfiker-Kleiner D; Bauersachs J
Clin Res Cardiol; 2019 Mar; 108(3):290-297. PubMed ID: 30121697
[TBL] [Abstract][Full Text] [Related]
53. Peripartum cardiomyopathy in an elderly patient with in-vitro fertilization pregnancy.
Shah P; Bhagwati A; Adlakh A; Patil S
J Assoc Physicians India; 2012 Apr; 60():72-4. PubMed ID: 23029752
[TBL] [Abstract][Full Text] [Related]
54. Pregnancy and peripartum cardiomyopathy. A comparative and prospective study.
Avila WS; de Carvalho ME; Tschaen CK; Rossi EG; Grinberg M; Mady C; Ramires JA
Arq Bras Cardiol; 2002 Nov; 79(5):484-93. PubMed ID: 12447499
[TBL] [Abstract][Full Text] [Related]
55. Pregnancy outcome after cabergoline treatment in early weeks of gestation.
Ricci E; Parazzini F; Motta T; Ferrari CI; Colao A; Clavenna A; Rocchi F; Gangi E; Paracchi S; Gasperi M; Lavezzari M; Nicolosi AE; Ferrero S; Landi ML; Beck-Peccoz P; Bonati M
Reprod Toxicol; 2002; 16(6):791-3. PubMed ID: 12401507
[TBL] [Abstract][Full Text] [Related]
56. Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy.
Sieweke JT; Pfeffer TJ; Berliner D; König T; Hallbaum M; Napp LC; Tongers J; Kühn C; Schmitto JD; Hilfiker-Kleiner D; Schäfer A; Bauersachs J
Eur Heart J Acute Cardiovasc Care; 2020 Mar; 9(2):173-182. PubMed ID: 29792513
[TBL] [Abstract][Full Text] [Related]
57. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
58. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
59. Asymptomatic left ventricular dysfunction in puerperal women: an echocardiographic-based study.
Vettori DV; Rohde LE; Clausell N
Int J Cardiol; 2011 Jun; 149(3):353-7. PubMed ID: 20199817
[TBL] [Abstract][Full Text] [Related]
60. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
